ADC Therapeutics (ADCT) Payables: 2019-2023
Historic Payables for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $23.3 million.
- ADC Therapeutics' Payables fell 3.21% to $23.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $95.9 million, marking a year-over-year increase of 46.13%. This contributed to the annual value of $24.8 million for FY2022, which is 105.50% up from last year.
- As of Q3 2023, ADC Therapeutics' Payables stood at $23.3 million, which was down 8.79% from $25.6 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Payables ranged from a high of $25.6 million in Q2 2023 and a low of $6,146 during Q3 2020.
- Moreover, its 3-year median value for Payables was $16.5 million (2022), whereas its average is $18.2 million.
- As far as peak fluctuations go, ADC Therapeutics' Payables skyrocketed by 215,156.73% in 2021, and later dropped by 11.02% in 2022.
- Quarterly analysis of 5 years shows ADC Therapeutics' Payables stood at $3.3 million in 2019, then reached $6,146 in 2020, then skyrocketed by 195,604.52% to $12.1 million in 2021, then skyrocketed by 105.50% to $24.8 million in 2022, then declined by 3.21% to $23.3 million in 2023.
- Its Payables was $23.3 million in Q3 2023, compared to $25.6 million in Q2 2023 and $22.2 million in Q1 2023.